LIFECARE ASA: Extraordinary General Meeting

Lifecare ASA, a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), will hold an Extraordinary General Meeting 17 September 2024, at 09:00 (CEST).

For the planned uplisting from Euronext Growth Oslo to Oslo Børs, a share consolidation is required to meet the NOK 10 per share listing requirement. Additionally, to address shareholders with fractional shares post-consolidation, the Board proposes General Meeting’s approval to acquire treasury shares.

The notice with complete agenda and documents is available on
https://lifecare.no/events/.

The meeting will be available here:
https://teams.microsoft.com/l/meetup-join/19%3ameeting_MzRkYWIyMjItYTU2MC00MGMwLTk3NDEtNTE4ZTZlYTk2NzRh%40thread.v2/0?context=%7b%22Tid%22%3a%22c5fbb1c6-4eb0-45db-9f3c-6e20ebcd710e%22%2c%22Oid%22%3a%2271082610-7009-40ed-92e6-70ae6bc35450%22%7d

About us
Lifecare ASA is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare’s main focus is to bring the next generation of Continuous Glucose Monitoring (“CGM“) systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors (“NTR“) on the sensor body for read-out of pressure variations. Lifecare’s sensor technology is referred to as “Sencell” and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

Fullmakt/Proxy

LIFECARE ASA: Extraordinary General Meeting